Immunological Effects of Interferon-alpha on Chronic Myelogenous Leukemia

Abstract

Treatment with interferon-α is effective for chronic myelogenous leukemia in the chronic phase (CML-CP), but the immunological mechanisms of the antileukemic effect of this substance are still unclear. The objective of this study was to investigate the immunological effects of interferon-α in CML patients. Markers of cellular activation and apoptosis, natural killer (NK) cell cytotoxicity and production of intracellular cytokines (IFN-γ, IL-2 and IL-4) were determined by flow cytometry in the peripheral blood mononuclear cells (PBMC) of 26 CML-CP patients before and 3, 6 and 9 months after IFN-α treatment. The results were correlated with the hematological response. In the whole group of patients, IFN-α use was followed by a significant increase of lymphocytes producing IL-2 and IFN-γ, an increase in NK activity and a decrease in the number of CD34⁺ cells. Out of 26 CML patients, 15 achieved hematological remission and 7 achieved partial cytogenetic remission after 9 months of IFN-α treatment. There was an increase in the percentage of CD8/FasL⁺, DR/CD3⁺, DQ/CD3⁺, CD34/Fas⁺, DR/CD56⁺, CD56/FasL⁺ cells and of IFN-γ- and IL-2-producing lymphocytes and an increase in NK cytotoxicity only in the group of patients who achieved complete hematological remission. Our results indicate that IFN-α use in CML-CP reduces the number of CD34⁺ cells, activates T cells, enhances stem cell apoptotic markers and increases the production of intracellular IFN-γ and IL-2 by lymphocytes. Taken together, these results indicate that the therapeutic effect of IFN-α in CML-CP is mediated at least in part by immunological mechanisms.

• Interferon-α
• Chronic myelogenous leukemia
• Immunophenotype
• Cytokines and NK cytotoxicity
• STAT3